Probiodrug Sponsoring Symposium to Share Research Findings in the Role of Pyroglutamated Abeta in the Progression of Alzheimer’s Disease
Probiodrug AG Strengthens Management Team and Expands Global Reach with Appointments of Ronald Black and Inge Lues
Probiodrug Provides further Insights into Science and Development of Glutaminyl Cyclase Inhibitor Development at 2013 Alzheimer’s Association International Conference
Probiodrug AG (Probiodrug) announced that it is sponsoring a symposium at the annual AD/PD™ 2013 – The 11th International Conference on Alzheimer’s & Parkinson’s Diseases, which is taking place March 6-10 in Florence, Italy. During this symposium, Probiodrug and Alzheimer’s disease experts from Brigham and Women’s Hospital, University of Leipzig, University of Amsterdam and the RIKEN Brain Science Institute will present evidence elucidating the role of pyroglutamated (pGlu) Abeta in the pathology of Alzheimer’s disease. The symposium, titled “pGlu Abeta as Target for AD-Treatment by Glutaminyl Cyclase Inhibition and Passive Immunization,” will take place on March 9, 2013 from 09:15 – 11:15 am in Hall B.
Dr. Konrad Glund, CEO of Probiodrug, commented, “There is increasing appreciation for the role of pGlu Abeta and glutaminyl cyclase (QC) in the development and progression of Alzheimer’s disease. QC inhibition has become one of the most exciting areas being evaluated in the study of this disease. While the research is nascent, we are very optimistic about the potential benefit of inhibiting QC with compounds such as our small molecule QC-Inhibitor PQ912, the first anti-pGlu-Abeta approach ready to be studied in patients.”
Probiodrug will be presenting several posters at the AD/PD 2013 conference on preclinical results on the proof of principle of the anti-pGlu-Abeta approach as well as complete data from the Company’s Phase 1 clinical study of PQ912. More information on the conference and scientific sessions may be found on the AD/PD website here: http://www.kenes.com/adpd.
About PQ912
PQ912 is a small molecule that targets glutaminyl cyclase (QC), an enzyme that catalyzes the formation of pyroglutamated Abeta, thus preventing the formation of highly toxic Abeta species including soluble oligomers. To date, 165 subjects have been enrolled in single- and multiple-dose phase 1 studies of PQ912, and the compound has been found to be safe and well-tolerated across the range of doses tested. It has been shown to inhibit up to 70% of QC activity in the cerebrospinal fluid of healthy subjects in a dose-dependent fashion.
About Probiodrug AG
Probiodrug is a biopharmaceutical company dedicated to the development of therapeutics to treat Alzheimer’s disease. Probiodrug’s core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes which play a central role in the maturation of hormones. Founded in 1997 by Prof. Dr. Hans-Ulrich Demuth and Dr. Konrad Glund, the Company has medical use and composition of matter patents related to the inhibition of glutaminyl cyclase, providing the Company with a dominant position in this field of research. Probiodrug is backed by institutions such as BB Biotech, Edmond de Rothschild Investment Partners, Goodvent/IBG, HBM, TVM Capital, Life Sciences Partners, Biogen Idec New Ventures, CFH Group, funds managed by Wellington Management and private investors. For more information, please visit www.probiodrug.de.
###
Company Contact:
Dr. Konrad Glund, CEO
Tel: +49 (345) 5559900
Email: konrad.glund@probiodrug.de